Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group

Olema Pharmaceuticals (NASDAQ:OLMA) had its target price dropped by The Goldman Sachs Group from $38.00 to $27.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 79.28% from the company’s current price.

A number of other equities research analysts have also commented on the company. JPMorgan Chase & Co. raised their price objective on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Guggenheim dropped their target price on Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday. Citigroup increased their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Thursday, January 22nd. Finally, Piper Sandler assumed coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Olema Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $42.00.

Olema Pharmaceuticals Price Performance

OLMA opened at $15.06 on Wednesday. The stock has a fifty day moving average of $23.81 and a 200-day moving average of $18.73. The firm has a market capitalization of $1.03 billion, a P/E ratio of -8.10 and a beta of 1.92. Olema Pharmaceuticals has a 12-month low of $2.86 and a 12-month high of $36.26. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. Equities analysts forecast that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ian T. Clark sold 264,800 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $29.73, for a total value of $7,872,504.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shane William Charles Kovacs sold 100,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $28.73, for a total value of $2,873,000.00. Following the completion of the transaction, the insider owned 139,727 shares in the company, valued at $4,014,356.71. This represents a 41.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 805,501 shares of company stock worth $23,003,832. Insiders own 16.36% of the company’s stock.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of OLMA. AQR Capital Management LLC bought a new stake in Olema Pharmaceuticals during the 1st quarter valued at approximately $172,000. Goldman Sachs Group Inc. raised its holdings in shares of Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after buying an additional 358,412 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Olema Pharmaceuticals by 216.8% during the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock valued at $521,000 after acquiring an additional 94,815 shares during the period. ProShare Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 21.1% in the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company’s stock worth $63,000 after purchasing an additional 2,569 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Olema Pharmaceuticals by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after purchasing an additional 242,997 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings surprised slightly to the upside — Olema reported ($0.50) EPS vs. consensus ($0.51), which triggered positive investor reaction and immediate share strength. Press Release OLMA Stock Jumps After Q4
• Positive Sentiment: HC Wainwright raised near‑term and multi‑year EPS forecasts across 2026–2030 (slightly less negative EPS), reiterated a “Buy” rating and kept a $38 price target — signaling improving economics expectations for the company. This analyst lift supports further upside sentiment. Analyst Note
• Positive Sentiment: Citigroup raised its price target sharply (from $60 to $62) and maintains a buy view — a material, bullish institutional price-target move that can draw attention from momentum and institutional buyers. Benzinga: Citigroup
• Positive Sentiment: Large external interest tied to Olema’s breast‑cancer drug: reports note a ~$68.7M wager related to the program targeting a 2027 launch, which underscores investor confidence and potential financing/support for commercial plans. Globe and Mail: $68.7M Bet
• Positive Sentiment: Clinical visibility: Olema (via Olema Oncology) will present preclinical data for palazestrant and OP‑3136 at AACR 2026 — continued scientific disclosure can reduce clinical uncertainty and support longer‑term valuation. Business Insider: AACR Presentation
• Negative Sentiment: Guggenheim trimmed its price target (from $40 to $38) though it kept a “Buy” rating — a slight headwind as some investors may see this as less bullish relative to higher targets. Benzinga: Guggenheim

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.